ANRO (Alto Neuroscience Inc) Net Profit

ANRO (Alto Neuroscience Inc) - company brandmark

Alto Neuroscience, Inc. (ANRO) is implementing precision psychiatry by developing targeted treatments for depression. The company's profit dynamics clearly demonstrate financial income, where the -0.08 mark records this metric. Business prospects rely on AI-driven biomarker analysis, which guarantees significant pricing power. However, success depends on overcoming scientific risks and fierce competition within the sector for developing new treatment mechanisms.

ANRO (Alto Neuroscience Inc) Company Net Income history from 02/21/2024 to 10/31/2026

Comprehensive metric breakdowns and analytics for Alto Neuroscience (ANRO)

- price and consensus price forecast:
Stock Quotes Alto Neuroscience Corp|ANRO - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Alto Neuroscience Corp|ANRO - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Alto Neuroscience|ANRO - Company Book Value|Market Capitalization to Net Assets altoneuroscience.com|ANRO - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Coefficient Alto Neuroscience, Inc.|ANRO - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Alto Neuroscience Inc|ANRO - Company Aggregate Debts|Debt to Book Value Alto Neuroscience Corp|ANRO - Company Long-Term Debts|Company Short-Term Loans and Borrowings Alto Neuroscience|Immediate Liquidity altoneuroscience.com
- net income and valuation multiples indicators:
ANRO - Net Profit
Fundamental valuation:ANRO, Alto Neuroscience Corp
Mass-produced product of Alto Neuroscience, Inc.

For Alto Neuroscience, Inc. (ANRO), this indicator reflects the ability to transform investments in the AI biomarker platform and clinical trial results into actual cash flow. Analyzing the company's profit chart allows for an assessment of the net financial result after all expenses, which is critical for determining business valuation ahead of potential merger and acquisition deals.

Direct competitors

Net Income Alkermes Corp|AVDL (Avadel Pharmaceuticals) - Net Profit|Net Profit atai.life|Net Income GHRS (GH Research)|MNMD (Mind Medicine (MindMed) Inc.) - Final Profit|Company Net Income Compass Pathways CMPS|LBRX (LB Corp) - Profit After Tax|DRUG - Company Net Income|Net Financial Result vandapharma.com VNDA|CYBN (cybin.com) - Net Income|Company Net Income NRx Pharmaceuticals Inc. (NRXP)|CING (Cingulate Inc) - Net Profit|Net Income silopharma.com (SILO)|Net Profit CPHI|CMND (Clearmind Medicine, Inc.) - Final Profit|Company Net Income Psyence Biomedical PBM|SciSparc Ltd. (SPRC) - Company Net Income|Seelos Therapeutics, Inc - Net Profit|VRPX - Net Profit|Karuna Therapeutics (KRTX) - Company Net Income